MCP-1 rs1024611 Polymorphism, MCP-1 Concentrations, and Premature Coronary Artery Disease: Results of the Genetics of Atherosclerotic Disease (GEA) Mexican Study

• Published in: Biomedicines 2024-06, Vol.12 (6), p.1292
• Main Authors: Posadas-Sánchez, Rosalinda, Velázquez-Sánchez, Fernando, Reyes-Barrera, Juan, Cardoso-Saldaña, Guillermo, Velázquez-Argueta, Frida, Antonio-Villa, Neftali Eduardo, Fragoso, José Manuel, Vargas-Alarcón, Gilberto
• Format: Article
• Language: English
• Subjects: Age; Arteriosclerosis; Atherosclerosis; Body mass index; Cardiovascular disease; Chemokines; Chi-square test; Coronary artery disease; Coronary heart disease; Coronary vessels; Diseases; Ethylenediaminetetraacetic acid; Gene polymorphism; genetic susceptibility; Genotype & phenotype; Heart attacks; Heart diseases; inflammation; Mexico; Monocyte chemoattractant protein; Monocyte chemoattractant protein 1; Monocytes; Polymorphism; polymorphisms; premature coronary artery disease; Proteins; Regression analysis; T cells; Variables; Vein & artery diseases; White people; Women
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines12061292

Monocyte chemoattractant protein-1 (MCP-1) participates in the initiation and progression of atherosclerosis. In vitro studies have reported that the rs1024611 polymorphism is associated with increased MCP-1 concentrations. The study aimed to define whether MCP-1 concentrations are associated with premature coronary artery disease (pCAD) and to establish whether variations in the rs1024611 polymorphism increase MCP-1 concentrations. rs1024611 polymorphism was determined in 972 pCAD patients and 1070 control individuals by real-time PCR. MCP-1 concentrations were determined by the Bio-Plex system. In the total population, men had higher MCP-1 concentrations when compared to women ( < 0.001). When stratified by rs1024611 genotypes, higher MCP-1 concentrations were observed in individuals compared to subjects ( = 0.023). When performing the analysis considering sex, the differences remained significant in women ( vs. , = 0.028 and vs. , = 0.008). MCP-1 concentrations were similar in pCAD patients and controls ( = 0.782). However, the independent analysis of the studied groups showed that in patients with the genotype, MCP-1 concentrations were significantly higher when compared to patients with the genotype ( = 0.009). Considering that the genotype increases MCP-1 concentration, we evaluated whether, in genotype carriers, MCP-1 concentrations were associated with pCAD. The results showed that for every ten pg/mL increase in MCP-1 concentration, the risk of presenting pCAD increases by 2.7% in genotype individuals. Individuals with the rs1024611 genotype present an increase in MCP-1 concentration. In those individuals, increased MCP-1 concentrations increase the risk of presented pCAD.